<DOC>
	<DOCNO>NCT01571284</DOCNO>
	<brief_summary>Primary Objective : To provide metastatic colorectal cancer patient access aflibercept document overall safety patient Secondary Objective : To document Health-Related Quality Life aflibercept patient population</brief_summary>
	<brief_title>Safety Quality Life Study Aflibercept Patients With Metastatic Colorectal Cancer Previously Treated With Oxaliplatin-Based Regimen</brief_title>
	<detailed_description>Each patient treat disease progression , unacceptable toxicity , death , Investigator 's decision patient 's refusal treatment ( whichever come first ) . Patients followed-up study treatment least 30 day last administration .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically proven adenocarcinoma colon rectum Metastatic disease Eastern Cooperative Oncology Group performance status 01 One one prior chemotherapeutic regimen metastatic disease . This prior chemotherapy must oxaliplatin contain regimen . Patients must progress oxaliplatin base chemotherapy . Patients relapse within 6 month completion oxaliplatin adjuvant chemotherapy eligible . Exclusion criterion : Prior therapy irinotecan Inadequate bone marrow , liver renal function : neutrophil &lt; 1.5x109/L , platelet &lt; 100x109/L , hemoglobin &lt; 9.0 g/dL , total bilirubin &gt; 1.5 x upper normal limit ( ULN ) , transaminases &gt; 3 x ULN ( unless liver metastasis present ) , alkaline phosphatase &gt; 3 x ULN ( unless liver metastasis present ) , serum creatinine &gt; 1.5 x ULN . Less 4 week prior radiotherapy , prior chemotherapy , prior major surgery ( surgical wound fully heal ) . Treatment investigational drug within prior 30 day . Treatment concomitant anticonvulsivant agent CYP3A4 inducer ( phenytoin , phenobarbital , carbamazepine ) , unless discontinue &gt; 7 day . History brain metastasis , uncontrolled spinal cord compression , carcinomatous meningitis new evidence brain leptomeningeal disease . Prior malignancy ( colorectal ) include prior malignancy patient disease free &lt; 5 year ( except adequately treat basal squamous cell skin cancer carcinoma situ cervix ) . Any follow within 6 month prior study inclusion : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , severe congestive heart failure , stroke transient ischemic attack . Any follow within 3 month prior study inclusion : severe gastrointestinal bleeding/hemorrhage , treatment resistant peptic ulcer disease , erosive oesophagitis gastritis , infectious inflammatory bowel disease , diverticulitis , pulmonary embolism uncontrolled thromboembolic event . Occurrence deep vein thrombosis within 4 week , prior study inclusion . Known dihydropyrimidine dehydrogenase deficiency . Predisposing colonic small bowel disorder symptom uncontrolled . Prior history chronic enteropathy , inflammatory enteropathy , chronic diarrhea , unresolved bowel obstruction/subobstruction , hemicolectomy , extensive small intestine resection chronic diarrhea . Known Gilbert 's syndrome . Unresolved unstable toxicity prior anti cancer therapy time inclusion . History anaphylaxis know intolerance atropine sulphate loperamide appropriate antiemetic administer conjunction FOLFIRI ( irinotecan , 5Fluorouracil , leucovorin ) . Severe acute chronic medical condition , could impair ability patient participate study . Urine proteincreatinine ratio ( UPCR ) &gt; 1 morning spot urinalysis proteinuria &gt; 500 mg/24h . Uncontrolled hypertension within 3 month prior study inclusion . Patients anticoagulant therapy unstable dose warfarin and/or outoftherapeutic range INR within 4 week prior study inclusion . Evidence clinically significant bleed predisposition underlie coagulopathy , nonhealing wound . Pregnant breastfeed woman . Patients reproductive potential agree use accept effective method contraception . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>